

## Overview of CML related sessions at EHA2026 Congress

June 11-14, 2026 in Stockholm (All Timings: CEST)

Time slots	Sessions
<b>CML sessions</b>	
June 12 (Friday)  10.00 – 11.30 CEST  Room: K1	<b>Satellite Symposium:</b> (Supported by Novartis) Chronic myeloid leukemia: How do we achieve quality survivorship?  Chair: Jorge Cortes (USA)  Program: <ul style="list-style-type: none"> <li>• CML: significant progress, remaining challenges (J. Cortes, USA)</li> <li>• Living with treatment: tolerability and quality of life in CML (D. Žáčková, Czech Republic)</li> <li>• Treatment-free remission: bridging evidence and clinical practice (F. Lang, Germany)</li> <li>• Future tools in CML: the potential role of AI (Koji Sasaki, Japan)</li> <li>• Audience Q&amp;A (all faculty)</li> <li>• Panel discussion and key takeaways (J. Cortes, USA)</li> </ul>
June 12 (Friday)  15.30 – 17.00 CEST  Room: A12 Hall	<b>Specialized Working Group Session:</b> Chronic myeloid leukemia  Chair: Andreas Hochhaus (Germany)  Program: <ul style="list-style-type: none"> <li>• Blast crisis: Lessons from real world (K. Sweet, USA)</li> <li>• Somatic mutations and chromosomal aberrations as predictors of blast crisis (T. Ernst, Germany)</li> <li>• PDX models to predict response to drug combinations in blast crisis (A. Laznicka, Czech Republic)</li> </ul>
June 13 (Saturday)  13.45 – 15.15 CEST  Room:	<b>Education Session:</b> Chronic myeloid leukemia (CML)  Chair: <ul style="list-style-type: none"> <li>• K. Machova Polakova (Czech Republic)</li> </ul>

Time slots	Sessions
AE1 Hall	Program: <ul style="list-style-type: none"> <li>• The crosstalk between CML and the niche (M. Schemionek, Germany)</li> <li>• Immune surveillance and treatment-free remission in CML (S. Mustjoki, Finland)</li> <li>• Choosing wisely from different treatment options (D. Réa, France)</li> </ul>
June 13 (Saturday) 8.30 – 9.30 CEST EHA Offices K22	<b>Inaugural Scientific Workshop of the iCMLf CURE Consortium</b> Chairs: <ul style="list-style-type: none"> <li>• Daniela Žáčková</li> <li>• Andreas Hochhaus</li> </ul>
Oral Sessions	
June 11 (Thursday) 16.45-18.00 CEST Room: A12 Hall	<b>Oral Session: Chronic myeloid leukemia – clinical</b> Chairs: <ul style="list-style-type: none"> <li>• Tim Brümmendorf (Germany)</li> <li>• Delphine Réa (France)</li> </ul> Program: <ul style="list-style-type: none"> <li>• S160: ASC4FIRST WK 144 ANALYSIS: CONTINUED SUPERIOR EFFICACY AND FAVORABLE SAFETY OF ASCIMINIB VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (Hughes T.)</li> <li>• S161: PONATINIB CONSOLIDATION AND DISCONTINUATION IN CML PATIENTS AFTER FAILED FIRST TFR ATTEMPT: UPDATED TFR OUTCOMES AND CHIP MUTATION ANALYSIS FROM THE RESTOP TRIAL (Carreño G.)</li> <li>• S162: HIGH RATES OF SUCCESSFUL SECOND STOP ATTEMPTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: RESULTS OF THE NAUT TRIAL (Kohlbrenner K.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• S163: EFFICACY AND SAFETY OF ADDING LOW DOSE TYROSINE KINASE INHIBITORS (TKIS) FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO DO NOT ACHIEVE OPTIMAL RESPONSE OR A DEEP MOLECULAR REMISSION (ALERT CML) (Yang J.)</li> <li>• S164: ENABLE: UPDATED EFFICACY AND SAFETY RESULTS OF ELVN-001, A NOVEL SELECTIVE ATP-COMPETITIVE INHIBITOR OF BCR::ABL1, IN PATIENTS WITH PREVIOUSLY TREATED CP-CML (Kim D.)</li> </ul>
<p>June 13 (Saturday)</p> <p>17.15 – 18.30</p> <p>Room: A9 Hall</p>	<p><b>Oral Session:</b> Chronic myeloid leukemia – Biology &amp; translational research</p> <p>Chair: Vignir Helgason (UK)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• S155: SINGLE-CELL GENETIC LINEAGE TRACING REVEALS PRE-EXISTING BLAST CRISIS-INITIATING CLONES AT CHRONIC PHASE CML DIAGNOSIS (Cao E.)</li> <li>• S156: SINGLE-CELL TRANSCRIPTOMICS-GUIDED FLOW CYTOMETRIC ANALYSIS OF INFLAMED MEGAKARYOCYTIC AND LYMPHOID PROGENITORS AT DIAGNOSIS IDENTIFIES CHRONIC PHASE CML AT HIGH RISK FOR BLAST CRISIS TRANSFORMATION (Ong T.)</li> <li>• S157: INFLUENCE OF NON-BCR::ABL1 SOMATIC MUTATIONS ON TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN CHRONIC MYELOID LEUKEMIA (Ciboddo M.)</li> <li>• S158: MOLECULAR MECHANISM OF ZDHHC19-MEDIATED JAK1 PALMITOYLATION DRIVING TKIS RESISTANCE IN CML LEUKEMIA STEM CELLS (Wang T.)</li> <li>• S159: INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEAL BIOLOGICAL HETEROGENEITY OF ACCELERATED-PHASE CHRONIC MYELOID LEUKEMIA AND IDENTIFY A BLAST-PHASE-LIKE SUBGROUP (Zhang X.)</li> </ul>

Time slots	Sessions
<b>Poster Sessions</b>	
June 12 (Friday) 18.45 – 19.45 Room: Hall A	<p><b>Poster session:</b> Chronic myeloid leukemia – Biology &amp; translational research</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• PF620: EARLY PREDICTION OF NILOTINIB RESPONSE IN CHRONIC MYELOID LEUKEMIA BY DRUG PLASMA CONCENTRATION AND SINGLE-CELL SIGNALING PROFILING (Gullaksen SE.)</li> <li>• PF621: EMERGENCE OF HIGHLY ASCIMINIB-RESISTANT CML VIA MINOR BCR::ABL1 SWITCH AND MUTATIONS (Štefíková B.)</li> <li>• PF622: FUNCTIONAL DETECTION OF TKI RESISTANCE IN LIVING CML CELLS USING THE FRET BIOSENSOR PICKLES (Mizutani T.)</li> <li>• PF623: TARGETING EPIGENETIC–METABOLIC CROSSTALK IN CML VIA BUTYRATE-INDUCED HDAC INHIBITION (Vacca R.)</li> <li>• PF624: PERIPHERAL BLOOD NEUTROPHIL QUANTITY AND MATURATION PREDICT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (Mihashi T.)</li> </ul>
June 12 (Friday) 18.45 – 19.45 Room: Hall A	<p><b>Poster Session:</b> Chronic myeloid leukemia – Clinical</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• PF625: FRONTLINE ASCIMINIB FOR CHRONIC PHASE CML: LONG TERM SAFETY AND EFFICACY IN THE ALLG CM13 ASCEND TRIAL (Yeung D.)</li> <li>• PF626: GENOMIC AND TRANSCRIPTOMIC FEATURES OF TRANSFORMED CHRONIC MYELOID LEUKEMIA IN BLAST PHASE (Bao M.)</li> <li>• PF727: PROGNOSTIC IMPACT OF ADDITIONAL SOMATIC MUTATIONS ON TKD DEVELOPMENT, MOLECULAR RESPONSE AND SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (Stuckey R.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• PF628: EFFICACY AND SAFETY OF PONATINIB IN PEDIATRIC PATIENTS WITH BCR::ABL- POSITIVE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML): PRELIMINARY RESULTS FROM THE INCB84344-102 STUDY (Locatelli F.)</li> <li>• PF629: LONG-TERM OUTCOMES OF VERY LOW-DOSE DASATINIB IN OLDER PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA: EXTENDED FOLLOW-UP OF THE DAVLEC PHASE 2 TRIAL (Murai K.)</li> <li>• PF630: THE SAFETY, TOLERABILITY, AND EFFICACY OF HS-10382 COMBINED WITH FLUMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CML: A PHASE 1B STUDY (Hu Y.)</li> <li>• PF631: PHASE II TRIAL OF DASATINIB IN COMBINATION WITH ASTX727 IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (Jabbour E.)</li> <li>• PF632: ASCIMINIB VERSUS SECOND-GENERATION TKIS IN CHRONIC-PHASE CML AFTER <math>\geq 2</math> PRIOR TKIS: A PROPENSITY SCORE-MATCHED ANALYSIS (Obaidallah N.)</li> <li>• PF633: TWO-YEAR OUTCOMES OF LOW-DOSE VERSUS STANDARD-DOSE DASATINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKAEMIA: A RETROSPECTIVE ANALYSIS (Verma S.)</li> <li>• PF634: HIGHER FIRST LINE TKI RESISTANCE IN ADOLESCENTS AND YOUNG ADULTS (AYA) WITH CHRONIC MYELOID LEUKEMIA. EVIDENCE FROM A POPULATION-BASED REGISTRY (Herranz Marti MJ.)</li> <li>• PF635: ASCIMINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INTERIM RESULTS FROM A PHASE II TRIAL (Jabbour E.)</li> <li>• PF636: TYROSINE KINASE INHIBITOR USE AND THE RISK OF NEURODEGENERATIVE DISEASE: A SWEDISH POPULATION-BASED COHORT STUDY (Wittström F.)</li> <li>• PF637: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ON CLINICAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA IN BLAST PHASE (Williams R.)</li> <li>• PF638: A SINGLE-CENTER, CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF HS-10382 IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) (Zhou L.)</li> <li>• PF639: EFFICACY AND SAFETY OF REDUCED-DOSE DASATINIB (50 MG/DAY) AS FIRST-LINE THERAPY IN CHRONIC MYELOID LEUKEMIA: RESULTS FROM A MULTICENTER REAL-WORLD STUDY BY THE SPANISH CML GROUP (de Paz Arias MR.)</li> </ul>

Time slots	Sessions
<p>June 13 (Saturday)</p> <p>18.45 – 19.45</p> <p>Room: Hall A</p>	<p><b>Poster Session:</b> Chronic myeloid leukemia – Biology &amp; translational research</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• PS1719: MORPHOLOGY-BASED CELL SORTING USING AI-DRIVEN GHOST CYTOMETRY COMBINED WITH SINGLE-CELL RNA SEQUENCING REVEALS POTENTIAL THERAPEUTIC TARGETS IN CML LEUKEMIC STEM CELLS (Takaku T.)</li> <li>• PS1720: CITE-SEQ RESOLVES THE LEUKEMIC STEM CELL HIERARCHY AND IMMUNE MICROENVIRONMENT IN CML DISEASE PROGRESSION VIA MACHINE LEARNING MODELS (Kirschner K.)</li> <li>• PS1721: DUAL TARGETING WITH PONATINIB AND CRIZOTINIB TO OVERCOME ASCIMINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA (Okabe S.)</li> <li>• PS1722: METABOLOMIC PROFILING REVEALS SUBTYPES WITH DISTINCT METABOLIC FEATURES AND PROGNOSIS IN CLL PATIENTS (Zhu H.)</li> <li>• PS1723: NEW 2-AMINOPYRIMIDINE PONATINIB DERIVATIVES AS POTENTIAL BCR-ABL1 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA (Ribeiro A.)</li> </ul>
<p>June 13 (Saturday)</p> <p>18.45 – 19.45</p> <p>Room: Hall A</p>	<p><b>Poster Session:</b> Chronic myeloid leukemia – Clinical</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• PS1725: CHRONIC MYELOID LEUKEMIA (CML) TREATMENT DISCONTINUATION AFTER A TWO-STEP DOSE REDUCTION. FINAL RESULTS OF THE PHASE 2 STUDY HALF (Mayer J. et)</li> <li>• PS1727: EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS (Jabbour E.)</li> <li>• PS1728: THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL (Wen B.)</li> <li>• PS1729: RISK OF PERMANENT FRONTLINE DISCONTINUATION DURING THE FIRST 36 MONTHS OF THERAPY WITH TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID</li> </ul>

Time slots	Sessions
	<p>LEUKEMIA: A “CAMPUS CML” STUDY WITH A NEW “AD HOC” SCORE PROPOSAL (Latagliata R.)</p> <p>PS1730: OPTIMAL TIMING AND PARAMETERS FOR TYROSINE KINASE INHIBITOR DOSE DE-ESCALATION AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (Lee S.)</p> <ul style="list-style-type: none"> <li>• PS1731: CHARACTERISTICS, TREATMENT AND OUTCOME OF 15 TO 18-YEAR-OLD ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA (CML): THE EXPERIENCE OF THE INTERNATIONAL REGISTRY OF CHILDHOOD CML (I-CML-PED STUDY) (Millot F.)</li> <li>• PF1732: KINETICS AND DURABILITY OF MOLECULAR RESPONSE AS PREDICTORS OF TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (Lee S.)</li> <li>• PF1733: UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) (Li W.)</li> <li>• PF1734: EARLY MOLECULAR KINETICS PREDICT DEEP MOLECULAR RESPONSE AND INFORM FRONTLINE TKI SELECTION IN PEDIATRIC CHRONIC MYELOID LEUKEMIA: A REAL-WORLD MULTICENTER STUDY (An W.)</li> <li>• PF1735: FRONT-LINE SECOND-GENERATION TKI THERAPY SIGNIFICANTLY IMPROVES THE SUCCESS RATE OF TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA: A MULTICENTER RETROSPECTIVE STUDY OF THE REAL WORLD (Jiang Q.)</li> <li>• PF1736: AGE-STRATIFIED ANALYSIS OF CML-CP IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS: A MULTICENTER RETROSPECTIVE STUDY (Huang J.)</li> <li>• PF1737: HOW MANY CHRONIC-PHASE CML PATIENTS STARTING TYROSINE KINASE INHIBITORS CAN ACHIEVE A PERSISTENT TREATMENT FREE REMISSION AND BE POTENTIALLY CURED? A SINGLE CENTER REAL-LIFE EXPERIENCE (D’ Adda M.)</li> <li>• PF1738: THERAPEUTIC STRATEGIES IN ADVANCED OR TKI-REFRACTORY CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS: THE ITALIAN EXPERIENCE (Quinti E.)</li> <li>• PF1739: MRD-TAILORED TREATMENT WITH DECITABINE COMBINED WITH DASATINIB IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE INDUCTION THERAPY: REAL-WORLD DATA IN RESOURCE-LIMITED SETTING (Kumar Nath U.)</li> </ul>

Time slots	Sessions
<b>For publication only</b>	
<p><b>Chronic myeloid leukemia – Biology &amp; translational research</b></p> <p><b>Abstracts:</b></p> <ul style="list-style-type: none"> <li>• PB2975: TREATMENT-FREE REMISSION (TFR) FOR NEWLY DIAGNOSED ACCELERATED PHASE CML (AP-CML) (Nicolini F.)</li> <li>• PB2976: SINGLE-CELL TRANSCRIPTOMIC AND CYTOGENETIC INSIGHTS IN A RARE VARIANT OF CHRONIC MYELOID LEUKEMIA SUGGEST A METABOLICALLY “PROTECTED” PHENOTYPE (Serrano-Gonzalo I.)</li> <li>• PB2977: MOLECULAR REMISSION AFTER TYROSINE KINASE INHIBITOR CESSATION IN CHRONIC MYELOID LEUKEMIA (CML): A SYSTEMATIC REVIEW AND META-ANALYSIS (Tungjitviboonkun S.)</li> <li>• PB2978: COMPLEX VARIANT TRANSLOCATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Zotova O.)</li> <li>• PB2979: BIOCHEMICAL AND MOLECULAR-GENETIC ARRAYS OF CHRONIC MYELOID LEUKEMIA: MANAGEMENT AND PROGNOSIS IMPACT (Musteata V.)</li> <li>• PB2980: DEVELOPMENT AND EVALUATION OF A NOVEL EXOSOME–SULFORAPHANE FORMULATION FOR ANTI-CANCER ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (Alkhataybeh B.)</li> <li>• PB2981: IMPACT OF BASOPHILIA AND EOSINOPHILIA ON IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA (Belkadi S.)</li> </ul>	
<p><b>Chronic myeloid leukemia – Clinical</b></p> <p><b>Abstracts:</b></p> <ul style="list-style-type: none"> <li>• PB2982: RESULTS OF TWO-STEP REDUCED-DOSE TKI THERAPY FOLLOWED BY TREATMENT-FREE OBSERVATION IN CML PATIENTS IN READIT (STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI) AND POST-STUDY FOLLOW-UP (Chelysheva E.)</li> <li>• PB2983: MANAGEMENT OF CML AND SECOND PRIMARY MALIGNANCIES IN THE ERA OF MODERN THERAPIES: REAL-WORLD STRATEGIES AND IMPACT ON CLINICAL OUTCOMES (Binotto G.)</li> </ul>	

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• PB2984: TKI DOSE INTENSITY AND TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS (Sannipoli D.)</li> <li>• PB2985: NINE-YEARS FOLLOW-UP OF THE PHASE I/II TRIAL OF IMATINIB DISCONTINUATION AFTER PIOGLITAZONE (EDI-PIO) IN CHRONIC MYELOID LEUKEMIA PATIENTS IN DEEP MOLECULAR RESPONSE (Pagnano K.)</li> <li>• PB2986: ULTRA-EARLY MOLECULAR RESPONSE AT 6 WEEKS OF ASCIMINIB THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (Wen B.)</li> <li>• PB2987: PREDICTORS OF OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE IN THE MODERN ERA (Short N.)</li> <li>• PB2988: PROSPECTIVE VALIDATION AND CLINICAL FOLLOW-UP OF DIGITAL PCR FOR BCR::ABL1 QUANTIFICATION IN CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE (CML-CP) (Ngo T.)</li> <li>• PB2990: LONG-TERM OUTCOMES OF PONATINIB TREATMENT IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA WITH OR WITHOUT THE T315 MUTATION (Lomaia E.)</li> <li>• PB2991: XS003 ELIMINATES NILOTINIB FOOD INTERACTIONS ENABLING OPTIMIZED DOSE REDUCTIONS, RESULTING IN MITIGATED QT-PROLONGATION RISK (Stenke L.)</li> <li>• PB2992: REAL-WORLD ANALYSIS OF FIRST-LINE TKI USE IN CML-CP: A 16-YEAR MULTICENTER EXPERIENCE (Huang J.)</li> <li>• PB2993: VERY LONG-TERM RESULTS OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOLLOWED BY TYROSINE KINASE INHIBITORS (TKI) FOR CP-CML (Michallet M.)</li> <li>• PB2994: INCIDENCE OF THE DEVELOPMENT OF PROTEINURIA FOLLOWING DASATINIB THERAPY IN CML PATIENTS AND ITS ASSOCIATION WITH THE OCCURRENCE OF PLEURAL EFFUSION (Musick E.)</li> <li>• PB2995: ELN RECOMMENDED RESPONSE MILESTONES PREDICT SURVIVAL AND DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING SECOND-GENERATION TYROSINE KINASE INHIBITOR (Chai G.)</li> <li>• PB2996: IMPACT OF BETA-THALASSEMIA TRAIT ON RISK STRATIFICATION AND OUTCOMES IN CHRONIC MYELOID LEUKEMIA (Shirinova A.)</li> <li>• PB2997: NONLINEAR ASSOCIATION BETWEEN PRE-DISCONTINUATION DOSE INTENSITY AND TREATMENT-FREE REMISSION OUTCOMES IN CHRONIC MYELOID LEUKEMIA: A REAL-WORLD ANALYSIS (Choi D.)</li> <li>• PB2998: CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND SOLID ORGAN TRANSPLANT: A 15-PATIENT CASE SERIES (Al Kurnas M.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• PB2999: EFFICACY AND SAFETY OF DIFFERENT NILOTINIB DOSES AS SECOND-LINE THERAPY IN PATIENTS WITH CML RECEIVED FIRST-LINE IMATINIB: A MULTICENTER RETROSPECTIVE STUDY (Yan H.)</li> <li>• PB3000: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS UNDER 18 YEARS OF AGE WITH CHRONIC MYELOID LEUKEMIA; LONG-TERM OUTCOMES (Benakli M.)</li> <li>• PB3001: FRONTLINE TREATMENT APPROACHES AND THEIR IMPACT ON THE OUTCOMES OF PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA WITH HYPERLEUKOCYTOSIS: A SINGLE CENTRE CHART REVIEW IN THE UNITED KINGDOM (Choy A.)</li> <li>• PB3002: IMPLEMENTATION OF A THERAPEUTIC DRUG MONITORING PROGRAM FOR IMATINIB DOSAGE INDIVIDUALIZATION IN PATIENTS WITH CML AND GIST: A PILOT STUDY (Romero Riquelme MA.)</li> <li>• PB3003: ANALYSIS OF THE IMPACT OF TYROSINE KINASE INHIBITORS ON RENAL FUNCTION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (Yang Y.)</li> <li>• PB3004: REAL-WORLD ASSESSMENT OF SYMPTOM BURDEN USING ESAS SCORE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH ASCIMINIB (Patiño AF)</li> <li>• PB3005: REAL-WORLD OUTCOMES OF ASCIMINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RESISTANT OR INTOLERANT TO AT LEAST TWO TYROSINE KINASE INHIBITORS: A SINGLE-CENTER RETROSPECTIVE STUDY IN POLAND (Wąclaw-Koziara J.)</li> <li>• PB3006: PRELIMINARY GLOBAL TRENDS CAPTURED THROUGH A DIGITAL QUALITY OF LIFE (QOL) TRACKER TOOL THAT HAVE AN IMPACT ON DAILY LIFE IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) (Saussele S.)</li> <li>• PB3007: TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA: A SURVEY OF PRACTICE OF HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM (Evans N.)</li> <li>• PB3008: REAL-WORLD PEDIATRIC CML IN A LOWER-MIDDLE-INCOME COUNTRY: LONG-TERM SURVIVAL, DEEP MOLECULAR RESPONSE, GROWTH IMPAIRMENT, AND QUALITY-OF-LIFE OUTCOMES OVER A DECADE (Yasar S.)</li> <li>• PB3009: REAL-WORLD EFFECTIVENESS AND SAFETY OF OLVEREMBATINIB IN CHRONIC MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (Yang Y.)</li> <li>• PB3010: PRE-TREATMENT COMORBIDITIES AND MANAGEMENT OF TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (Kirkizlar T.)</li> <li>• PB3011: TIMING TO MAJOR MOLECULAR RESPONSE (MMR) DOES NOT IMPACT OVERALL SURVIVAL IN CHRONIC PHASE CML: A MULTICENTRE REAL-WORLD PERUVIAN STUDY (López Córdoba N.)</li> <li>• PB3012: GENERIC VERSUS BRANDED IMATINIB IN CHRONIC MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND</li> </ul>

Time slots	Sessions
	<p>META-ANALYSIS OF 21 OBSERVATIONAL STUDIES (Biwasw S.)</p> <ul style="list-style-type: none"> <li>• PB3013: EVALUATION OF THE EFFICACY OF IMATINIB IN NEWLY DIAGNOSED CML PATIENTS WITH T(9;22;?)(Q34;Q11.2;?) THREE-WAY TRANSLOCATION (Wang W.)</li> <li>• PB3014: ANALYSIS OF SECONDARY MALIGNANCIES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS – A SINGLE-CENTER EXPERIENCE FROM POLAND (Biernat M.)</li> <li>• PB3015: SINGLE-TUBE MULTIPLEX ABSOLUTE QUANTIFICATION OF BCR::ABL1 TRANSCRIPTS FOR SENSITIVE MRD MONITORING IN CHRONIC MYELOID LEUKEMIA (Van Hermelen D.)</li> <li>• PB3016: RAPID MOLECULAR RESPONSES AND PRESERVED QUALITY OF LIFE WITH ASCIMINIB IN CHRONIC MYELOID LEUKEMIA: A REAL-WORLD STUDY (Lin B.)</li> <li>• PB3017: TOWARDS INDIVIDUALIZED TREATMENT STEWARDSHIP IN CHRONIC MYELOID LEUKEMIA BASED ON COMBINATION OF MOLECULAR DATA AND MATHEMATICAL MODELING (Roeder I.)</li> <li>• PB3018: PAX5::MLLT3 FUSION DEFINES A HIGH-RISK SHIFT TOWARD LYMPHOID BLAST EVOLUTION IN CML (Caridi M.)</li> <li>• PB3019: DIFFERENT BCR::ABL1 TRANSCRIPT LEVELS @ 3 AND 6 MONTHS MIGHT BE USEFUL IN IDENTIFYING WARNING/RESISTANT CML PATIENTS WHEN USING 2G-TKIS AS FRONTLINE TREATMENT (Stagno F.)</li> <li>• PB3020: LONG-TERM OUTCOMES OF CHRONIC MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS TREATED WITH GENERIC IMATINIB AS FIRST-LINE AND ITK2 AS SECOND-LINE THERAPY : A RETROSPECTIVE STUDY (Rekab N.)</li> <li>• PB3021: A PHASE 3 STUDY OF OLVEREMBATINIB (HQP1351) IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA: POLARIS-2 TRIAL IN PROGRESS (Jabbour E.)</li> <li>• PB3022: ASC4KIDS-2 TRIAL-IN-PROGRESS: ASCIMINIB IN PEDIATRIC CHRONIC MYELOID LEUKEMIA WITH OR WITHOUT T315I (Metzler M.)</li> <li>• PB3024: REAL-WORLD EXPERIENCE OF TREATMENT-FREE REMISSION AFTER TKI DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: WITH REDUCED FREQUENCY OF MOLECULAR MONITORING OF BCR::ABL1 QPCR TEST (Perusini M.)</li> <li>• PB3025: STAMP INHIBITORS IMPROVE EARLY MOLECULAR RESPONSE (BCR::ABL1 &lt;5% AT 3 MONTHS) IN CHRONIC-PHASE CML: A MULTICENTER REAL-WORLD COHORT FROM SOUTHERN CHINA (Huang L.)</li> <li>• PB3026: COMPARISON OF THE INCIDENCE OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA RECEIVING TYROSINE KINASE INHIBITORS WITH REPRESENTATIVES OF THE GENERAL POPULATION (Shnalieva N.)</li> <li>• PB3027: CHRONIC MYELOID LEUKAEMIA IN THE PAEDIATRIC AND YOUNG ADULT POPULATION – A MULTI-</li> </ul>

Time slots	Sessions
	<p>CENTRE RETROSPECTIVE STUDY (Wilson A.)</p> <ul style="list-style-type: none"> <li>• PB3028: REAL WORLD MOLECULAR RESPONSE TO INHIBITOR ALLOSTERIC IN ADULT CHRONIC MYELOID LEUKEMIA: A MEXICAN MULTICENTER RETROSPECTIVE COHORT (Cabrera Rodríguez Á)</li> <li>• PB3029: REAL-WORLD PERFORMANCE OF ELTS AND SOKAL FOR PREDICTION OF EARLY MOLECULAR RESPONSE IN CHRONIC-PHASE CML TREATED WITH MIXED FRONTLINE TKIS (Li W.)</li> <li>• PB3030: MOLECULAR AND CLINICAL OUTCOMES OF FIRST-LINE TKIS IN A MULTIETHNIC CML COHORT UNDER UNIVERSAL ACCESS IN MALAYSIA: INTERIM ANALYSIS OF THE MYMPN RWE STUDY (Chew L.)</li> <li>• PB3031: ASCIMINIB IN CHRONIC-PHASE CML AFTER PRIOR TKI INTOLERANCE OR RESISTANCE: REAL-WORLD OUTCOMES FROM A SINGLE-CENTER COHORT (Kolotsiou A.)</li> <li>• PB3032: ADOLESCENT AND YOUNG ADULT CHRONIC MYELOID LEUKEMIA IN MALAYSIA: 25-YEAR EPIDEMIOLOGICAL PROFILE AND TREATMENT OUTCOMES FROM A MALAYSIAN SINGLE-CENTRE ANALYSIS (Jamhuri S.)</li> <li>• PB3033: REAL-WORLD PERFORMANCE OF ELTS AND SOKAL FOR PREDICTION OF EARLY MOLECULAR RESPONSE IN CHRONIC-PHASE CML TREATED WITH MIXED FRONTLINE TKIS (Grasu D.)</li> <li>• PB3034: THERAPEUTIC RESULTS OF SECOND-GENERATION TKI FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (Fakhfakh Derbel Y)</li> <li>• PB3035: ONE VS. 2 VS. <math>\geq 3</math> TET2 MUTATIONS IN CHRONIC MYELOMONOCYtic LEUKEMIA: CO-MUTATION PATTERNS AND PROGNOSTIC CORRELATES (Muhammed Y.)</li> <li>• PB3036: EXPERIENCE WITH PONATINIB IN CHRONIC MYELOID LEUKAEMIA IN PARAGUAY (Zarza J et al.)</li> <li>• PB3037: TRIAL IN PROGRESS: REAL-WORLD STUDY OF ASCIMINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHINA (ASC4CN) (Li W.)</li> <li>• PB3038: FLUMATINIB IN CHRONIC MYELOID LEUKEMIA WITH RARE BCR-ABL TRANSCRIPTS: A REPORT OF 4 CASES AND ANALYSIS OF EFFICACY CHARACTERISTICS (Zhang Q.)</li> <li>• PB3039: REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN PEDIATRIC CHRONIC MYELOID LEUKEMIA: A MEXICAN COHORT STUDY (Rodríguez Cedeño ER)</li> <li>• PB3040: ADDITIONAL CHROMOSOMAL ABNORMALITIES AT DIAGNOSIS PREDICT INFERIOR EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA: A SINGLE-CENTER STUDY (Rao S.)</li> <li>• PB3041: ASCIMINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A REAL-WORLD ANALYSIS OF EFFICACY AND SAFETY (Zhang X.)</li> <li>• PB3042: COMPARATIVE REVIEW OF EMERGING TYROSINE KINASE INHIBITORS IN THE PIPELINE FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (Beg M.)</li> <li>• PB3043: IMPACT OF ADDITIONAL CYTOGENETIC ABNORMALITIES ON THE EVOLUTION OF CHRONIC MYELOID</li> </ul>

Time slots	Sessions
	<p>LEUKEMIA: A RETROSPECTIVE STUDY FROM NORTHERN MOROCCO (Arahou T.)</p> <ul style="list-style-type: none"> <li>• PB3044: MYELOID BLAST TRANSFORMATION OF CHRONIC MYELOID LEUKEMIA INTO ACUTE MYELOID LEUKEMIA: TWO DISTINCT EVOLUTIONARY PATHWAYS IN THE TKI ERA (Mayssa D.)</li> <li>• PB3045: A STUDY ON PREGNANCY SUCCESS, BIRTHS, AND MISCARRIAGES IN CML-CP PATIENTS DURING TYROSINE KINASE INHIBITOR THERAPY: A SINGLE-CENTER ANALYSIS (Sato E.)</li> <li>• PB3046: REAL-WORLD OUTCOMES OF FRONTLINE IMATINIB IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE MONOCENTRIC SURVIVAL ANALYSIS (Chajai I)</li> <li>• PB3047: CLONAL HYPEREOSINOPHILIA IN A 20-YEAR-OLD MALE PRESENTING WITH NEUROPATHY AND VISUAL DISTURBANCE: CASE REPORT (Alpay J.)</li> <li>• PB3048: DIFFUSE LARGE B-CELL LYMPHOMA DURING DEEP MOLECULAR RESPONSE IN CML: BLAST CRISIS OR SECOND MALIGNANCY? (Chenbah W.)</li> <li>• PB3049: EXTRAMEDULLARY T-LYMPHOBLASTIC TRANSFORMATION DURING CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE (Yahia A.)</li> <li>• PB3050: CHRONIC MYELOID LEUKEMIA DEVELOPING AFTER BREAST CANCER REMISSION (Gogokhia T.)</li> </ul>